RBC plans to price 8% reverse convertibles linked to Biogen Idec

By Angela McDaniels

Tacoma, Wash., Aug. 21 – Royal Bank of Canada plans to price 8% annualized reverse convertible notes due Aug. 28, 2015 linked to the common stock of Biogen Idec Inc., according to an FWP filing with the Securities and Exchange Commission.

Interest will be payable monthly.

The payout at maturity will be par in cash unless Biogen Idec shares fall below the protection price, 80% of the initial share price, during the life of the notes and finish below the initial share price, in which case the payout will be a number of Biogen Idec shares equal to $1,000 divided by the initial share price.

RBC Capital Markets LLC is the agent.

The notes will price Aug. 26 and settle Aug. 29.

The Cusip number is 78010UX36.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.